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Abstract
Diabetes and obesity have been implicated as risk factors for dementia. However, metabolic mechanisms and
associated signalling pathways have not been investigated in detail in frontotemporal dementia. We therefore here
characterised physiological, behavioural and molecular phenotypes of 3- and 8-month-old male tau knock-in
(PLB2TAU) vs wild-type (PLBWT) mice. Homecage analysis suggested intact habituation but a dramatic reduction
in exploratory activity in PLB2TAU mice. Deficits in motor strength were also observed. At 3 months, PLB2TAU
mice displayed normal glucose handling but developed hyperglycaemia at 8 months, suggesting a progressive
diabetic phenotype. Brain, liver and muscle tissue analyses confirmed tissue-specific deregulation of metabolic and
homeostatic pathways. In brain, increased levels of phosphorylated tau and inflammation were detected alongside
reduced ER regulatory markers, overall suggesting a downregulation in essential cellular defence pathways. We
suggest that subtle neuronal expression of mutated human tau is sufficient to disturb systems metabolism and protein
handling. Whether respective dysfunctions in tauopathy patients are also a consequence of tau pathology remains to
be confirmed, but could offer new avenues for therapeutic interventions.
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Introduction
Alzheimer’s disease (AD) is the most common form of de-
mentia, characterised by a progressive loss of memory and
decline in cognitive function. Histopathologically, end-stage
AD is defined by two extracellular aggregates, β-amyloid and
neurofibrillary tangles (NFTs). Though both pathologies must
be present for a diagnosis of AD, it is important to note that
NFTs correlate better with cognitive decline and disease dura-
tion and tau-only pathology is observed in isolation, for ex-
ample in frontotemporal dementia (FTD; [1]).
The microtubule-associated protein tau is essential for cy-
toskeletal stability and assembly, its biological activity is reg-
ulated by post-translational modifications, e.g. abnormally
hyperphosphorylated tau is detrimental to neuronal function
and ultimately leads to paired helical filaments (PHFs), the
main constituents of NFTs. Hyperphosphorylation of tau
may also promote conformational changes, which can lead
to seeding and spreading of pathological protein species
throughout the brain [2].
Considering the heterogeneity between and within
the different types of dementia, it appears likely that
tau pathology may initially be caused by a complex
interplay between several multifactorial components,
on the background of an ageing brain. To date, there
is increasing evidence supporting a link between neu-
rodegenerative disorders and metabolic dysfunction, in-
cluding glucose intolerance and insulin resistance [3].
A number of studies have examined the association
between type 2 diabetes (T2D) and FTD, with some
suggesting that impaired insulin secretion, glucose in-
tolerance and hyperglycaemia are risk factors [3].
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Peripheral insulin resistance is a central feature of di-
abetes, but increasing evidence suggests that neuronal
insulin signalling also regulates cognitive function [4,
5]. Conversely, impaired tau function may contribute to
metabol ic changes seen in dement ia pa t ien ts .
Accordingly, a recent study demonstrated that deletion
of tau can lead to impaired hippocampal responses to
insulin via alterations in IRS1 (insulin receptor sub-
strate 1) and PTEN (phosphatase and tensin homo-
logue) signalling [5]. Another report found that knock-
out of the insulin receptor (IR) resulted in a substantial
increase in hyperphosphorylated tau at sites associated
with neurodegenerative diseases [6]. For these observa-
tions, cellular dyshomeostasis such as ER stress may
be the common denominator, since ER disruptions oc-
cur in both metabolic and neurodegenerative disease,
and polymorphisms in ER key mediators are key risk
factors for proteinopathies such as AD and FTD [7, 8].
Specifically, the ER plays a central role in proteostasis
[9] and responses to physiological challenges. Hence, a
range of pathological and age-related stimuli can dis-
rupt ER homeostasis resulting in accumulation of un-
folded or misfolded proteins. Cerebral proteinopathies
and also T2D are characterised by disturbances in re-
spective restorative ER function, with the ‘unfolded
protein response’ (UPR) alleviating stress during an
acute high turnover of proteins. However, chronic ac-
tivation of the UPR can lead to cell dysfunction and
apoptosis [10], and hence, restoration of normal ER
function may offer a potential therapeutic approach
for various diseases including FTD and T2D [11–13].
Importantly, a recent study in a mouse model of
frontotemporal dementia (Tg4510) showed that treat-
ment with the PERK inhibitor GSK2606414 restored
protein synthesis rates, protected against neuronal loss
and reduced levels of ER stress markers phospho (p)-
PERK, p-eIF2α and ATF4 [12]. Similarly, another
study in a T2D model utilised the ER chaperone
tauroursodeoxycholic acid (TUDCA), which led to nor-
malisation of hyperglycaemia, enhanced insulin action
and restoration of insulin sensitivity [14]. Overall, the
UPR is implicated in both FTD and T2D relevant dis-
ease processes [15], but its exact function is not fully
elucidated yet [16].
Here, we sought to investigate the role of central vs periph-
eral insulin signalling and ER stress pathways in a murine
knock-in model of frontotemporal dementia (FTD), termed
PLB2TAU. These mice express a single copy of mutated
hTau (2N4R TauP301L + R406W), which yields brain phospho-
tau pathology and disturbances in activity, cognition and
sleep, relevant for an FTD-like phenotype [17]. We provide
evidence that neuronal metabolic, inflammatory and ER stress
pathways are affected by abnormal hTau expression,
ultimately leading to a systemic diabetic phenotype and
tissue-specific disturbances in insulin signalling, indicative
of a crucial role for tau in metabolic and homeostatic
regulation.
Materials and Methods
Animals
Three-month-old male PLBWT (‘WT’, n = 7) and PLB2TAU
(n = 14) mice and eight-month-old male PLBWT (n = 17) and
PLB2TAU (n = 10) mice were generated as previously de-
scribed [17]. Of note, the PLBWT mice, which serve as con-
trols for all PLB lines, were originally created as littermates
from the parental PLB1Double mice. All PLB lines are main-
tained at Charles River, UK, on a C57BL6 background, and
all lines are regularly crossed with unrelated C57BL6/J (elite
breeders from Charles River). All mice were housed and test-
ed in accordance with UK Home Office regulations, i.e. the
EU directive 63/2010E and the Animal (Scientific
Procedures) Act 1986. Mice were bred (Charles River) and
delivered to our facility several weeks before testing. Animals
were housed in a climate-controlled holding room (20–21 °C,
60–65%, relative humidity) with ad libitum access to water
and food with a 12-h day/night cycle (lights on at 7 am).
In Vivo Characterisation
Glucose, Insulin, Pyruvate Tolerance Tests and EchoMRI
Tail blood glucose was determined using an AlphaTRAK
glucometer (Berkshire, UK). Glucose (GTT) and insulin tol-
erance (ITT) tests were performed in 5-h-fasted mice, and
pyruvate tolerance tests (PTT) were performed in 15-h-
fasted mice. Body weights and fasting blood glucose (time
0) were recorded, followed by i.p. injection of glucose, insulin
or pyruvate: GTT, 2 mg/g body weight dose of glucose (20%
w/v glucose); ITT, 0.75 IU/g body weight dose of human
insulin (Humulin R; Eli Lilly); PTT, 2 mg/g body weight dose
of pyruvate (20% w/v pyruvate). Blood glucose levels were
determined at 15, 30, 60 and 90 min post-injection. Body
composition (adiposity and lean body mass) was assessed
using EchoMRI as described in previous studies (EchoMRI,
Houston, TX, USA; [18]).
PhenoTyper Home Cage Activity
Locomotor and circadian activity were assessed using the
PhenoTyper (Noldus, The Netherlands; [19]) home cage ob-
servation system. Activity (distance moved) was recorded for
7 days and data extracted in 1-h or 10-min bins. The first 3 h of
recording served as habituation to a new environment. The
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mean hourly activity was calculated over 24 h. The animals
were given free access to weighted amount of food and water
during PhenoTyper home cage analysis and the amount of
food consumed was recorded.
RotaRod
Automated four-lane accelerating RotaRods (UgoBasile NG
Rotarod 1.3.2R) were used to examine motor coordination
and motor learning. Testing occurred on 2 consecutive days
with 4 trials per day (5-min intervals) using an acceleration
from 1 to 45 rpm over 5 min.
Ex Vivo Molecular Characterisation
Blood Plasma Collection
Mice were fasted for 5-h and 20 μl of blood was collected from
the tail of each mouse into a BD Microtainer SST Tube (BD
Biosciences, CA, USA). Tubes were left to coagulate at room
temperature for 30-min and centrifuged at 7500 rpm for 15-min
at 4 °C. Serum was aliquoted and stored long-term at − 80 °C.
Insulin ELISA
An Insulin ELISA (Merck Millipore, Cat No: EZRMI-13K)
was used to quantify insulin levels in PLB2TAU mice using
blood serum samples from 5-h-fasted mice. This assay was
carried out following manufacturers’ instructions and absor-
bance measured at 450 nm and 590 nm using BMG labtech
FLUOstar Omega plate reader (BMG Labtech, Germany).
Brain, Muscle and Liver Tissues
Eight-month-old mice were fasted for 5-h and an i.p. injection
of insulin (10 mU/g body weight) was administered. Mice
were sacrificed by neck dislocation; brains, muscle and liver
removed and snap-frozen in liquid nitrogen and stored at −
80 °C for future use. Brain tissue was homogenised in NP40
lysis buffer (1 M HEPES, 5 M sodium chloride (NaCl), 0.1 M
ethylenediaminetetraacetic acid (EDTA) (1%), NP-40 (Sigma,
Dorset, UK): pH = 7.6). For tau Western blot detection, heat-
stable fractions were isolated by further heating the brain su-
pernatant at 90 °C for 10 min before being spun (14,000 rpm,
4 °C, and 10 min) and the resulting supernatant collected.
Muscle or liver tissue was homogenised in RIPA lysis buffer
(10 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 1% Triton, 1%
sodium deoxycholate, 5 mM EDTA, 1 mM NaF, 1 mM
NaOV: pH = 7.4). Both buffers were supplemented (1 tablet/
10 ml) with complete protease inhibitors (Roche) and
PhosStop tablets (Roche). Homogenates were centrifuged
(14,000g, 4 °C, 20 min) and the supernatant collected and
stored at − 80 °C.
Protein Analyses
Sample protein concentration was adjusted using a BCA pro-
tein assay (Sigma, Dorset, UK) to a final concentration of
3 μg/μl. Samples were prepared with 15 mM dithiothreitol
(DTT; Sigma), lithium dodecyl sulphate (LDS, Thermo
Fisher Scientific, Paisley, UK), and NP40 lysis buffer and
were boiled for 10 min at 70 °C and separated on a pre-cast
NuPage 4–12% sodium Bis-Tris electrophoresis gels.
Electrophoresis was conducted for 45 min at 200 V in
MOPS buffer. Proteins were transferred onto a nitrocellulose
(0.45-μm pore size, Invitrogen, UK) membrane using wet
transfer (NuPage transfer buffer in dH2O with 10% methanol)
at 25 V for 1 h. Tris-buffered saline with Tween (TBST)
(0.05% Tween, 50 mMTrizma base, 150 mMNaCl) was used
for washing (3 × 15-min washes). After transfer, membranes
were blocked (5% milk powder in TBST) for 1 h at RT.
Subsequently, membranes were washed in TBST (3 ×
10min) and incubated overnight at 4 °C in primary antibodies.
Primary antibodies (Suppl. Table 1) were prepared using 5%
BSA, 0.05% sodium azide and TBST. The following day,
membranes were washed and incubated in appropriate sec-
ondary antibodies (Suppl. Table 1). Western blots were
visualised using freshly prepared enhanced chemiluminescent
substrate (ECL; 0.015% hydrogen peroxide (H2O2), 30 μM
coumeric acid in 1.25 mM luminol). Images were captured
using a Vilber-Fusion chemiluminescence-imaging camera
and Fusion Software (PEQLAB).
Quantification
Coomassie Blue was used as a protein loading control for
Western blots as described previously [20]. All loading con-
trol images are provided as a supplementary document
(Suppl.1). Densitometric analysis of 16-bit Western blots im-
ages was performed using ImageJ (NIH) software. Data for
phospho markers were first normalised to total protein prior to
expression relative to WT controls; all other markers were
normalised to total protein and expressed relative to controls.
Puromycin Assay
Male PLBWT (n = 12) and PLB2TAU (n = 9) mice (8 months
old) were anaesthetised and unilateral intracerebroventricular
injections perfromed of either puromycin (25 mg/2.0 ml;
Sigma, Dorset, UK), vehicle (10% DMSO in artificial cere-
brospinal fluid, aCSF), negative control (puromycin and
thapsigargin (0.5 μg/μg; Tocris, Abingdon, UK)); coordi-
nates: − 2 mm anterioposterior, 2 mm mediolateral, and
1.5 mm dorsoventral), as described previously [21]. Mice
were sacrificed by cervical dislocation 2 h after the injection.
The cerebellum was removed, and half brains dissected for
total protein extraction. Incorporation of puromycin was
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detected viaWestern blots as described above, using overnight
incubation with an anti-puromycin antibody (1:5000;
Millipore), prior to secondary antibody labelling, imaging
and quantification.
Quantitative Polymerase Chain Reaction (qPCR)
Total RNA was isolated from cortical and liver mouse
tissue using TRIReagent (Ambion, Warrington, UK) ac-
cording to the manufacturer’s protocol. cDNA was syn-
thesised from 1 μg of total RNA using the bioline
cDNA synthesis kit (Bioline, London, UK). Target
genes were amplified by quantitative polymerase chain
reaction (PCR) using GoTaq qPCR Master Mix
(Promega, Southampton, UK) in a Roche LightCycler®
480 System (Roche Diagnostics, Burgess Hill, UK).
Relative gene expression was calculated using the com-
parative Ct method (2−δδCt). Primer sequences used for
qPCR are listed in Suppl. Table 2. The geometric mean
of three of the most stable reference genes (Y-Whaz,
NoNo, 18S, GAPDH or BetaActin) were used to nor-
malise data.
Primary Hippocampal Cell Culture
Hippocampal cultures from 1- to 3-day-old C57BL/6 mice
were prepared as described previously [22]. Briefly, the hip-
pocampus was dissected and dissociated in HEPES-buffered
saline (HBS; 130 mM NaCl, 5.4 mM KCl, 1.8 mM CaCL2,
1 mM MgCl2, 10 mM HEPES, 25 mM D-glucose, pH 7.4)
containing 1mg/ml protease typeXIV. Tissue was triturated in
HBS, centrifuged and re-suspended in medium. Neurobasal
medium was supplemented with 5% foetal bovine serum, 2%
B27, 1% L-glutamine and 0.025% glutamate at 37 °C in a
humidified atmosphere with 5% CO2 and maintained for
5 days. Subsequently, cells were treated with thapsigargin
(0.5 μM) for 24 h followed by RNA extraction used as posi-
tive control for ER stress.
Statistical Analysis
Statistical analysis was performed using Prism (V6,
GraphPad). Comparisons between two groups applied
Student’s two-tailed t tests, multiple groups were com-
pared using parametric or non-parametric analysis of
variance (one-way or two-way ANOVA) followed by
Bonferroni post-tests as appropriate for selected data
sets of interest. Nonlinear regression analysis with one-
phase decay was used for habituation data. For all data,
p < 0.05 was considered reliable.
Results
Body Weights and Metabolic Phenotypes at 3 Months
of Age
Body weights and glucose and insulin intolerance were
examined in 3-month-old male PLB2TAU mice and their
age-matched controls. PLB2TAU mice weighed less cf.
WT (~ − 10%; p = 0.009; Fig. 1(a)). A glucose tolerance
test revealed normal glucose handling for all time
points, with no significant difference in total glycaemic
excursion (Fig. 1(b, c)). However, PLB2TAU mice
displayed early signs of insulin resistance, i.e. higher
blood glucose levels were detected 90 min post bolus
injection of insulin (Fig. 1(d)), alongside an overall in-
crease in total glucose excursion (p = 0.0178; Fig. 1(e))
compared with WT mice.
Body Composition and Metabolic Phenotype
at 8 Months of Age
Body adiposity, body weights and glucose tolerance were next
examined in 8-month-old male PLB2TAU mice. Transgenic
PLB2TAU mice continued to weigh less (− 17%; p = 0.0001)
than PLBWTcontrols and EchoMRI results indicated this to be
due to a lower lean body mass (− 14%; p < 0.001) (Fig. 1(f,
g)). Furthermore, 5-h-fasted PLB2TAU mice presented with
elevated blood glucose levels and severe glucose intolerance
over all time points during glucose tolerance tests (GTTs,
p < 0.001) (Fig. 1(h, i)). Additionally, these mice were also
dramatically insulin resistant following a bolus injection of
insulin (p < 0.05) (Fig. 1(j, k)). Pyruvate tolerance tests
(PTTs) were performed in 15-h-fasted mice, since pyruvate
bolus injection elicits a glycaemic excursion that reflects he-
patic gluconeogenesis (Fig. 1(l, m)). PLB2TAU mice had sig-
nificantly higher blood glucose levels following the pyruvate
challenge during the full 90-min time course (p < 0.001), with
a significant increase in overall blood glucose levels (AUC;
p < 0.0001). Basal insulin levels were also determined to be
increased in PLB2TAU mice compared with age-matched
controls (p = 0.0007; Fig. 1(n)). Following this, markers
for gluconeogenesis were probed in PLB2TAU mice
(Fig. 1(o)). In T2D, the liver exhibited higher levels
of gluconeogenesis, consistent with hepatic insulin resis-
tance. Gene expressions of fatty acid synthase (FAS, +
135%; p = 0.0147), phosphoenolpyruvate carboxykinase
(PEPCK, + 102%; p = 0.0001), glucose 6-phosphatase
(G6Pase, + 56%; p = 0.0085) and fibroblast growth fac-
tor 21 (FGF21, + 66%; p = 0.0147) were upregulated
compared with age-matched PLBWT controls. Overall,
these results are indicative of a severe diabetic pheno-
type in PLB2TAU mice at this age.
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Circadian Activity and Habituation
Analysis of motor activity over 3 h during habituation to a
novel environment revealed a significant difference between
genotypes at 8 months of age (Fig. 2(a)): PLB2TAU mice were
less active during habituation compared with age-matched
controls (F(3,642) = 61.25, p = 0.0001), particularly during
the first hour. Data were fitted to an exponential decay func-
tion, which indicated a significant reduction in the initial (Y0)
activity of PLB2TAU mice (p = 0.0001,) yet no differences in
the eventual plateau phase, or rate at which activity declined
(K). Circadian activity in habituated animals, when considered
in mean hourly time bins over 5 consecutive days (Fig. 2(b)),
showed the typical circadian and ultradian patterns with
higher nocturnal activity profiles in both genotypes. There
was however a reduction in the motor activity of PLB2TAU
mice compared with the WT; this was especially apparent
during the dark phase (8 pm), where only controls showed
the typical ultradian nocturnal activity peak. Despite differ-
ences in body weight and activity, food intake appeared at
comparable levels in transgenic mice vs controls (Fig. 2(c)).
Motor Performance
Motor coordination and motor learning tests using a RotaRod
task identified a significant impairment in motor abilities cf.
controls. PLB2TAU mice dismounted faster overall all trials,
indicative of a general motor impairment and reduced motor
strength (p = 0.0001; Fig. 2(c)). Both PLB2TAU (+ 55%;
p < 0.01) and PLBWT (+ 60%; p < 0.001) showedmotor learn-
ing over the 2-day period with an extended latency to decent
over the course of the 8 trials. However, motor performance in
trial 8 (p < 0.05; Fig. 2(d)) and improvement (trial 1 vs trial 8)
was significantly better in WT vs PLB2TAU mice.
Insulin Signalling in the Brain and Peripheral Tissue
Next, we investigated the molecular basis of the diabetic phe-
notype of the PLB2TAU mice, by probing for established
markers of the insulin signalling pathway (Fig. 3(e)) in brain,
muscle and liver tissues, as the major insulin targeting tissues.
Insulin resistance, a characteristic feature of T2D, causes di-
minished downstream effects in target tissues. In liver tissue,
Fig. 1 Metabolic phenotype of 3- and 8-month-old male PLBWT (n = 17)
and PLB2TAU (n = 10) mice. Three-month-old (PLBWT (n = 7) and
PLB2TAU (n = 14)): (a) Body weights. (b, c) Glucose tolerance test
(GTT) and quantification of area under the curve (AUC) for total
glycaemic excursions. d, e) Insulin tolerance tests (ITTs) and quantifica-
tion of AUC. 8-month-old: (f) Body weights. (g) EchoMRI. h, iGTTand
quantification of AUC for total glycaemic excursions. j, k ITTs and quan-
tification of AUC. l,m Pyruvate tolerance tests (PTTs) and quantification
of AUC. n Quantification of insulin levels in serum. o Quantification of
qPCR gluconeogenesis markers in liver tissue. N.S., not significant.
****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05
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PLB2TAU mice presented with a decrease in phosphorylated
IRβ (also when expressed relative to total IR) (− 22%, p =
0.0031; Fig. 3(c)); there was no change in protein levels of
total IRβ, total IRS1, total AKT or total ribosomal S6
(Fig. 3(c)). A decrease in phosphorylated AKTand phosphor-
ylated ribosomal S6 was identified in muscle and liver (−
21%, − 36%; p = 0.02 and p = 0.0005, respectively).
In contrast to liver, skeletal muscle, a predominant site of
insulin-mediated glucose uptake, displayed a significant
increase in IRβ phosphorylation relative to total levels
(38%, p = 0.0010; Fig. 3(b)), with no change in overall total
expression. Total IRS1, phosphorylated AKT and phosphory-
lated ribosomal S6 were decreased, indicating diminished
net muscle insulin signalling (− 46%, − 31%, − 33%; p =
0.002, p = 0.044 and p = 0.0640, respectively). Total levels
of both AKT and ribosomal S6 remained unchanged
(Fig. 3(b)).
IR signalling in the brain does not necessarily follow the
changes in peripheral tissue, and indeed we here detected evi-
dence for enhanced brain insulin signalling at 8 months of age,
with some changes already occurring at 3 months. For the youn-
ger cohort, there was no change in protein levels of IRS1, phos-
phorylated JNK, total JNK, phosphorylated ribosomal S6 or total
ribosomal S6 (Fig. 3(d)) in PLB2TAU brain tissue cf. WTs.
However, an increase was detected in phosphorylated IRβ (+
20%, p = 0.041; Fig. 3(d)) and phosphorylated AKT (+ 25%,
p = 0.002; Fig. 3(d)) at 3 months. At 8 months, a 1.5-fold
increase in phosphorylated IRβ emerged in PLB2TAU cf. age-
matched WT (p= 0.0029; Fig. 3(d)), with total levels remaining
unchanged. The downstream substrate IRS1 revealed a decrease
in total levels (− 39%, p = 0.0067; Fig. 3(d)) but increased levels
of both phosphorylated AKT and phosphorylated ribosomal S6
(~ 1.5-fold) were identified for the older age group only
(PLB2TAU vs PLBWT controls: p’s < 0.001; Fig. 3(d)).
Phosphorylated Tau and Inflammatory Markers
in the Brain
As previously described, PLB2TAU mice express mutated hu-
man tau, resulting in increased levels of phosphorylated tau at
both PHF-1 and CP-13 epitopes at 6 months of age [17]. We
here first compared the expression of mouse and human tau
using qPCR. Human tau expression was confirmed in
PLB2TAU mice only, with no change in mouse tau expression
at 8 months of age between both genotypes (Fig. 4(a, b)).
Next, we analysed protein levels of tau phosphorylation in
brain tissue of 8-month-old PLB2TAUmice. As in our previous
report [17], protein levels of HT7-reactive human tau con-
firmed an extra band in PLB2TAU mice in the heat-stable frac-
tion, while total tau levels quantified by the AT-5 (3 bands)
were unaltered (Fig. 4(c)). When AT5 bands were considered
independently, significant increases in protein levels of 55-
and 60-kDa tau species were detected (+ 35%, + 39%; p =
0.0077, p = 0.0143, respectively). Further analysis confirmed
Fig. 2 Behavioural data in 8-month-old PLBWT (n = 17) and PLB2TAU
(n = 10) mice during PhenoTyper home cage analysis and RotaRod task.
a Nonlinear regression analysis (one-phase decay) of activity (distanced
moved, cm/10 min) during the 3-h habituation period in the PhenoTyper
home cage. b Average hourly activity over 24 h. c Average food intake
per day relative to body weight. d Latency to fall from RotaRod was
overall reduced in PLB2TAU mice vs PLBWTwith both groups displaying
motor learning (e, trial 1 vs. trial 8). ****p < 0.0001, ***p < 0.001,
**p < 0.01, *p < 0.05
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elevated levels of PHF-reactive phospho-tau (epitope Ser396/
Ser404) in PLB2TAU mice relative to corresponding PLBWT
samples (Fig. 4(c); p = 0.0001), with individual bands demon-
strating a significant increase (55- and 60-kDa tau species;
Fig. 4(c); all p < 0.0001). Similar changes in tau phosphoryla-
tion were observed for the CP-13 epitope (Ser202) (Fig. 4(d);
all p < 0.01).
Activation of inflammatory pathways as reported in human
FTDwas further investigated in brain tissue of PLB2TAUmice
by measuring astrocyte (GFAP) and microglia/macrophage
(Iba1) markers. Surprisingly, lower levels of ionised
calcium-binding adapter molecule 1 (Iba1; Fig. 4(e)) sug-
gested a decrease in activated microglia in PLB2TAU mice
compared with WT (p = 0.0023; Fig. 4(e)). The astrocyte
marker glial fibrillary acid protein (GFAP) (Fig. 4(e)), on the
other hand, was overall increased. Specifically, there was a 2-
fold increase in the 45-kDa band and 1.6-fold rise of the 50-
kDa band (all p’s = 0.0001; Fig. 4(e)), indicative of
astrogliosis.
ER Stress in Liver Tissue
As ER stress has also been reported to play a crucial role in
peripheral insulin resistance, impaired insulin secretion and the
development of T2DM, ER-relevant gene and protein analyses
were next investigated in the liver. Here, significantly elevated
levels of ER stress markers were detected in PLB2TAU mice
(Fig. 5): Gene expressions of BiP (+ 54%, p = 0.0009); eIF2α
(+ 41%, p= 0.0407), ATF6 (+ 232%, p < 0.0001) and IRE1α (+
51%, p = 0.0087) were upregulated compared with age-matched
PLBWT controls; there was also a trend for increased levels of
ATF4 (+ 50%, p = 0.07). Spliced XBP1 expression was not
changed, and decreased levels of total XBP1 in PLB2TAU mice
Fig. 3 Insulin signalling in the brain vs periphery. (a) Representative
Western blots for insulin signalling markers in the muscle, liver and
brain. Quantification of markers in (b) muscle, (c) liver and (d) brain.
PLBWT data for the 3-month group were omitted for clarity, but used for
statistical analysis, i.e. each age group was assessed relative to their age-
matched PLBWT controls. e Simplified schematic showing insulin signal-
ling cascade. All phospho markers are expressed relative to total expres-
sion. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05
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compared with controls did not reach significance (− 23%, p =
0.08).
Protein analysis in the liver confirmed a significant
increase in BiP expression compared with PLBWT con-
trols (+ 75%, p = 0.003), alongside phosphorylated
IRE1α (+ 175%, p = 0.0046). There was also a trend
for increased levels of phosphorylated eIF2α (+ 14%,
p = 0.0509), but no change in total levels of IRE1α or
e IF2α (− 23 and − 8%; p = 0 .091 , p = 0 .5287 ,
respectively).
Fig. 5 ER stress gene and protein expression in liver and brain tissue of 8-
month-old PLBWT (n = 17) and PLB2TAU (n = 10) mice. a Gene expres-
sion changes in ER stress–related markers in liver tissue. bWestern blots
of phosphorylated IRE1α, total IRE1α, BiP, phosphorylated eIF2α and
total eIF2α in liver tissue. c Quantification of ER stress markers in liver
tissue. d Simplified ER stress signalling cascade. e Gene expression
changes in brain tissue. Positive control (+ve): thapsigargin-treated pri-
mary hippocampal cultures. f Western blots of phosphorylated eIF2α,
total eIF2α, BiP, phosphorylated IRE1α and total IRE1α in brain tissue.
g Quantification of ER stress markers in brain tissue. All phospho
markers are expressed relative to total expression. *p < 0.05, **p > 0.01,
***p < 0.001 and ****p < 0.0001
Fig. 4 Expression of (phosphorylated) tau and inflammatory markers in
8-month-old PLBWT (n = 17) and PLB2TAU (n = 10) mice. a
Quantification of human tau expression via qPCR. b Quantification of
mouse Tau expression (qPCR). c Quantification of individual bands of
total Tau (AT5). dQuantification of individual bands and total expression
for phospho Tau (PHF1) expression relative to total Tau. e Quantification
of individual bands and total expression for second phospho tau marker
(CP13) relative to total Tau. fQuantification of 45 kDa, 50 kDa, and total
glial fibrillary acid (GFAP, astrocyte marker) and microglia marker Iba1
levels. g Representative Western blots of phosphorylated tau and inflam-
mation markers in both PLBWT and PLB2TAU male mice at 8 months of
age. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p<0.05
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ER Stress in Brain Tissue
ER markers were investigated next in brain tissue (Fig. 5).
Expression of ER stress–related genes in cortical brain tissue
revealed a decrease in several markers: The ER chaperone BiP
(Grp78), bound on the luminal side to the three main trans-
membrane ER signalling proteins (IRE1α, PERK and ATF6)
thus keeping them in an inactive state, was downregulated cf.
WTcontrols (− 49%, p = 0.0098). ATF4was also significantly
decreased in PLB2TAU mice (− 41%, p = 0.0054), as was
CHOP, its downstream regulator of cell death (− 29%, p =
0.0065). There was no change in expression of spliced
XBP1 (active form) relative to total levels of XBP1; however,
total XBP expression was also significantly decreased com-
pared with age-matched controls (− 47%, p = 0.0002). For the
third UPR arm (ATF6), no change in expression compared
with controls was detected (p = 0.77).
Protein analysis further confirmed a significant decrease in
ER stress markers for BiP expression (− 37%, p = 0.004) and
phosphorylated activated IRE1α compared with age-matched
PLBWTcontrols (− 18%); total IRE1α protein levels remained
unchanged (p = 0.04). Phosphorylated eIF2α was also signif-
icantly lower (− 34%, p = 0.0047). Overall, this suggests a
striking down-regulation of two ER stress arms in brain tissue
of PLB2TAU mice compared with PLBWT controls.
Protein Translation Rates
The drastic decrease in brain ER stress markers suggested
that overall protein translation could be affected (decreased) in
PLB2TAU mice. Conversely, it has been previously proposed
that an increase in protein turnover can result in a reduction of
ER stress–related markers [23]. We therefore next employed a
functional readout of ER protein translation in brain tissue. This
was achieved via the puromycin assay (SunSeT; [24]), which
determined protein synthesis rates in the PLB2TAU mice in vivo
(Fig. 6). In line with the proposed decreased levels of ER stress
markers associated with higher ER demand, and in contrast to
the lower activation of UPR pathwyas, the overall protein trans-
lation in the PLB2TAU mice was found to be increased at
8 months of age (+ 56%, p < 0.001).
Discussion
Here, we report that PLB2TAU mice with low levels of neuro-
nal human mutated tau expression [17] display the onset of
T2D-like symptoms (impaired insulin tolerance) at 3 months
of age, gradually progressing with age, where elevated blood
insulin levels and impaired glucose handling as well as insulin
resistance can be observed at 8 months of age. This phenotype
may be due to common pathophysiological mechanisms asso-
ciated with both T2D and tau pathologies. Although not much
is known about the link between tauopathies and insulin re-
sistance in humans, it has been suggested that CNS tau pa-
thology can affect peripheral physiology. One of the key met-
abolic deficits in T2D is peripheral insulin resistance, where
the capacity of insulin to stimulate glucose uptake is impaired.
Peripheral metabolic disturbances previously examined in
tauopathy mouse models indicated that insulin resistance can
promote tau phosphorylation and cognitive decline [25]. In
addition, elevated insulin and triglyceride levels have been
found in FTD patients [26], and a clinical diagnosis of FTD
was associated with a history of T2D [27].
T2D patients also exhibit an increased rate of hepatic gluco-
neogenesis, resembling the PLB2TAU phenotype [28]. Of note,
previous studies have suggested a link between metabolic and
motor function [5, 29], though the PLB2TAU phenotype is
Fig. 6 Protein synthesis rates in 8-month-old PLBWT (n = 12) and
PLB2TAU (n = 9) brain tissue. Protein synthesis rates were measured
using an adaption to the SUnSET assay. a Representative Western blot
of puromycin (indicative of newly synthesised proteins), vehicle (10%
DMSO in aCSF), negative control (-ve, puromycin and thapsigargin) and
the left (L) hemisphere over a 2-h period in both PLBWT and PLB2TAU
mice at 8 months of age. b Quantification of protein synthesis rates.
PLB2TAUmice exhibited an increase in protein translation rates compared
to PLBWT controls. ***p < 0.001
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ultimately more akin to a lean T2D phenotype [30], since it was
not associated with increased food intake or body weight.
However, the loss of lean body mass (muscle tissue) in the
PLB2TAU mice likely contributed to the motor phenotype
observed.
Older PLB2TAU mice displayed impaired glucose handling,
increased hepatic gluconeogenesis and features of insulin resis-
tance, with the hyperglycaemic state likely a direct result of im-
paired insulin signalling and responsible for the motor and activ-
ity impairments observed, as also proposed by previous studies
[5, 29]. Hypoactive traits were also consistent with previous data
[17] and most evident during the beginning of the dark (activity)
phase. Respective deficits have been reported in other mouse
models of FTD [31, 32], although the diabetic status in these
models remained unexplored, with phenotypes commonly attrib-
uted to tau expression in neuronal motor centres. In patients with
spinal and bulbar muscular atrophy, reduced expression of IR
and IRS1 has been reported; the resultant motor deficit correlated
with the level of insulin dysfunction [33]. A reduction in lean
muscle mass has also been reported in early-stage human AD
cases [34]; the authors suggested this to be a result of AD pa-
thology or due to a shared pathway between AD and metabolic
deficits. Thus, as the metabolic phenotype of PLB2TAU mice is
by design a result of brain-specific tau expression, we conclude
that peripheral metabolic changes can result as a consequence of
tau pathology and are not necessarily the actual primary cause.
A role for tau protein in the regulation of insulin signalling
in the brain and periphery has recently been proposed by other
studies, largely in line with our data [4, 5, 35], though a com-
plex picture is emerging by closer inspection of recent key
publications. Marciniak et al. [5] hypothesised that loss of
tau function in tau KO mice impairs brain insulin signalling
and results in metabolic dysfunction, demonstrated by a
reduced hippocampal response to insulin. Here, the opposing
changes in insulin signalling in brain vs periphery in PLB2TAU
mice are somewhat contrary to the assumption that brain in-
sulin signalling can supress hepatic gluconeogenesis. In agree-
ment with our data, Sajan et al. reported elevated levels of
AKT, protein kinase C and phosphorylated tau in brain tissue
of insulin-resistant high-fat-fed mice and ob/ob mice [36].
They also revealed that increased central insulin signalling
triggered an increase in hepatic gluconeogenesis, glucose in-
tolerance and systemic insulin resistance.
The phenotype of PLB2TAU mice also differs in some aspects
to that of THY-Tau22 mice [37], which displayed hyperactivity
and hypoinsulinemia but no glucose intolerance, as opposed to
hypoactivity and hyperinsulinemia as well as impaired glucose
clearance seen in our tau model. Both models have in common
an apparent increase in brain IR signalling amidst a lower body
weight and altered metabolic status. As THY-Tau22 mice have
much higher levels of gene expression and pathology,we suggest
that the link between central and peripheral insulin signalling is
not necessarily linear and unidirectional, and very likely brain-
region and pathology-type specific. Tau’s role in insulin resis-
tance in the low-expression PLB2TAU mice suggests a complex
dysregulation rather than a generalised downregulation. Indeed,
converging signalling pathways beyond those directly responsi-
ble for neuronal IR signalling may be upregulated as a compen-
satory reaction. Nevertheless, the mutated hTau gene of
PLB2TAU mice may be affected due to its hyperphosphorylated
state, and this may also affect the principal role of (endogenous)
tau as a microtubule-stabilising protein. This is in line with accu-
mulating evidence suggesting a link between tau pathology and
metabolic disorders. We therefore here propose that normal tau
function is essential to maintain central and peripheral insulin
signalling, via a detrimental cycle that implicates neuronal tau
in systemic as well as neuronal metabolic regulation.
Despite mounting evidence suggesting a relationship be-
tween AD and metabolic disorders, it is not known to what
extent the two hallmarks of the disease (amyloid and tau)
contribute to peripheral or central metabolic abnormalities.
Our data support the possibility that impaired tau function
may be crucial for insulin resistance, but it should be noted
that metabolic impairments have also been reported in APP-
associated mouse models of AD (e.g. APP/PSEN1 mice [38]
and 3xTg-AD [39]. Importantly, insulin resistance was more
severe in the presence of tau pathology, further confirming a
crucial role for tau. Additionally, neuron-specific, low expres-
sion of human beta-secretase BACE1 (PLB4 mice) also led to
systemic diabetes [18], further confirming that brain-specific,
dementia-relevant pathologies can dramatically affect systems
physiology.
Peripherally, increased ER stress is a central feature of T2D
and insulin resistance [40]. Similar to neurones, pancreatic β-
cells are susceptible to ER stress as their ER is highly active
due to the secretory demand requiring a high level of quality
control. During hyperglycaemia, the sustained demand for
insulin results in programmed cell death of β-cells [41]. Of
note, db/dbmice, a common model of insulin resistance, have
elevated levels of essential ER markers such as phosphorylat-
ed eIF2α and spliced of XBP [41]. This is in accordance with
our finding of elevated levels of phosphorylated IRE1α, BiP
and increased expression of ATF6 in the liver. Of note,
PLB2TAU mice displayed a tissue-specific ER stress profile
with for example the ATF6 arm being dramatically affected
in liver but not brain. ATF6’s role in liver pathology is in
agreement with previously reported links to fatty liver disease
and diabetes [42].
Recently, a relationship between neuronal UPR and FTD
has been suggested [8, 12], with an upregulation of PERK and
eIF2α in both the FTD brain and tauopathy mouse models.
Surprisingly, our data showed not only a tissue-specific down-
regulation of eIF2α but also a reduction in other ER stress–
related markers through protein and gene expression analysis
in brain tissue (contrasting dramatically with the liver pheno-
type). In line with our data, reduced brain eIF2α expression
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had been reported previously in tauopathy mouse model [16].
Here, despite a generalised reduction in ER-related proteins,
protein translation was elevated, which agrees with lower
eIF2α levels, as phospho-eIF2α inhibits the protein synthesis
and controls translation [23]. Elevated protein synthesis may
be associated with increased inflammation, as indicated by the
raised GFAP levels, in line with neuroinflammation reported
in pathologically vulnerable regions in FTD. Heightened
astrogliosis in PLB2TAU mice is also in keeping with similar
investigations in other tauopathy mouse models [43, 44], as
well as the role of astrocytes in brain homeostasis.
The role of microglia in FTD is not as well elucidated [44],
and interestingly, our data suggest a potential reduction of Iba1
in PLB2TAU mice. Importantly, this phenotype is in line with
reports of reduced levels of microglia in human AD [45] amidst
elevated levels of other inflammatory markers such as GFAP
and CD88 [46, 47]. The latter is associated with phagocytosis
and clearance, while Iba1 is essential for microglia motility and
synaptic support [45]; hence, a loss of Iba1 functionwould be in
line with dementia pathology. In addition to this, Streit and
colleagues revealed that non-activated microglia colocalised
with neuronal structures positive for tau such as neurofibrillary
tangles and neuritic plaques [48]. It was suggested that tau
pathology does not trigger microglial activation; instead,
microglial degeneration and loss of microglial neuroprotection
are likely a result of ageing rather than being associated with
AD pathology. Recent proposals of opposing M1/M2 pheno-
types [49] as well as suggestions of additional (‘dark’) microg-
lia [50] highlight the complexity of microglia (patho-)physiol-
ogy. These aspects require careful age- and region-specific as-
sessments in tauopathy models in future studies.
Overall, our results suggest a link between neuroinflamma-
tion, ER stress, insulin resistance and tau pathology. Subtle
neuronal expression of mutated human tau caused inflamma-
tion and the dysregulation of ER housekeeping mechanisms,
and was sufficient to produce diabetes-like, tissue-specific
changes in metabolic regulation. This pathway may offer
new avenues for the development of therapeutic interventions.
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